Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 6/20 | 0.79 |
| ▸ | HTR2C | P28335 | 1/20 | 0.79 |
| ▸ | MAPT | P10636 | 3/20 | 0.76 |
| ▸ | PPARG | P37231 | 2/20 | 0.76 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.76 |
| ▸ | SLC22A8 | Q8TCC7 | 2/20 | 0.76 |
| ▸ | SLC22A11 | Q9NSA0 | 2/20 | 0.76 |
| ▸ | ALB | P02768 | 1/20 | 0.76 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.74 |
| ▸ | PGR | P06401 | 3/20 | 0.72 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.72 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.67 |
| ▸ | APEX1 | P27695 | 3/20 | 0.67 |
| ▸ | ABCC4 | O15439 | 3/20 | 0.67 |
| ▸ | LMNA | P02545 | 2/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.67 |
| ▸ | PKM | P14618 | 1/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cefetamet SCHEMBL6567051 | 1.00 | NR1I2 (0.79) | NR1I2HTR2CMAPTPPARGSLC22A6 | |
| Cefetamet SCHEMBL27492189 | 1.00 | NR1I2 (0.79) | NR1I2HTR2CMAPTPPARGSLC22A6 | |
| Cefetamet SCHEMBL10587826 | 1.00 | NR1I2 (0.79) | NR1I2HTR2CMAPTPPARGSLC22A6 | |
| Cefetamet SCHEMBL8795245 | 1.00 | NR1I2 (0.79) | NR1I2HTR2CMAPTPPARGSLC22A6 | |
| Cefetamet SCHEMBL7863727 | 1.00 | NR1I2 (0.79) | NR1I2HTR2CMAPTPPARGSLC22A6 | |
| Cefetamet SCHEMBL11328620 | 1.00 | NR1I2 (0.79) | NR1I2HTR2CMAPTPPARGSLC22A6 | |
| Cefetamet SCHEMBL10587831 | 1.00 | NR1I2 (0.79) | NR1I2HTR2CMAPTPPARGSLC22A6 | |
| Cefetamet SCHEMBL151099 | 1.00 | NR1I2 (0.79) | NR1I2HTR2CMAPTPPARGSLC22A6 | |
| Cefetamet SCHEMBL65620 | 1.00 | NR1I2 (0.79) | NR1I2HTR2CMAPTPPARGSLC22A6 | |
| Cefetamet SCHEMBL2586142 | 0.99 | NR1I2 (0.78) | NR1I2HTR2CMAPTPPARGSLC22A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4112053-A1 | TREATMENT OF SYNUCLEINOPATHIES | Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (DE) | 2023-01-04 | — | — | EP | disclosed |
| EP-3525788-B1 | TREATMENT OF SYNUCLEINOPATHIES | DEUTSCHES ZENTRUM FUER NEURODEGENERATIVE ERKRANKUNGEN E V DZNE (DE) | 2022-05-25 | — | — | EP | disclosed |
| US-10918628-B2 | Treatment of synucleinopathies | DEUTSCHES ZENTRUM FÜR NEURODEGENERATIVE ERKRANKUNGEN E. V. (DZNE) (DE) | 2021-02-16 | — | — | US | disclosed |
| US-20200239460-A1 | TRPV1 ANTAGONISTS INCLUDING DIHYDROXY SUBSTITUENT AND USES THEREOF | PURDUE PHARMA LP (US) | 2020-07-30 | — | — | US | disclosed |
| EP-2880033-B1 | CYCLIC UREA- OR LACTAM-SUBSTITUTED QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA LP (US) | 2020-06-17 | — | — | EP | disclosed |
| US-10450308-B2 | TRPV1 antagonists including dihydroxy substituent and uses thereof | PURDUE PHARMA L.P. (US) | 2019-10-22 | — | — | US | disclosed |
| US-20190282552-A1 | Treatment of synucleinopathies | DEUTSCHES ZENTRUM FÜR NEURODEGENERATIVE ERKRANKUNGEN E. V. (DZNE) (DE) | 2019-09-19 | — | — | US | disclosed |
| EP-3173411-B1 | TRPV1 ANTAGONISTS INCLUDING DIHYDROXY SUBSTITUENT AND USES THEREOF | PURDUE PHARMA LP (US) | 2018-05-09 | — | — | EP | disclosed |
| US-9873691-B2 | TRPV1 antagonists including dihydroxy substituent and uses thereof | PURDUE PHARMA L.P. (US) | 2018-01-23 | — | — | US | disclosed |
| US-20170183337-A1 | TRPV1 ANTAGONISTS INCLUDING DIHYDROXY SUBSTITUENT AND USES THEREOF | PURDUE PHARMA L.P. | 2017-06-29 | — | — | US | disclosed |
| US-9273043-B2 | TRPV1 antagonists including dihydroxy substituent and uses thereof | PURDUE PHARMA L.P. (US) | 2016-03-01 | — | — | US | disclosed |
| US-9085561-B2 | Cyclic urea- or lactam-substituted quinoxaline-type piperidines as ORL-1 modulators | PURDUE PHARMA L.P. (US) | 2015-07-21 | — | — | US | disclosed |
| US-20150011529-A1 | AZETIDINE-SUBSTITUTED QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF | PURDUE PHARMA L.P. | 2015-01-08 | — | — | US | disclosed |
| US-20140350056-A1 | TRPV1 ANTAGONISTS INCLUDING DIHYDROXY SUBSTITUENT AND USES THEREOF | PURDUE PHARMA L.P. | 2014-11-27 | — | — | US | disclosed |
| US-20140329829-A1 | TRPV1 ANTAGONISTS INCLUDING DIHYDROXY SUBSTITUENT AND USES THEREOF | SHIONOGI & CO., LTD. (JP) | 2014-11-06 | — | — | US | disclosed |
| US-20140128346-A1 | PHOSPHORUS-SUBSTITUTED QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF | PURDUE PHARMA L.P. (US) | 2014-05-08 | — | — | US | disclosed |
| US-20140045830-A1 | CYCLIC UREA- OR LACTAM-SUBSTITUTED QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF | SHIONOGI & CO., LTD. (JP) | 2014-02-13 | — | — | US | disclosed |
| EP-0393066-B1 | CEPHALOSPORIN ANTIBIOTICS | UPJOHN CO (US) | 1994-02-02 | — | — | EP | disclosed |
| US-5223496-A | Veterinary medicine | THE UPJOHN COMPANY (US) | 1993-06-29 | — | — | US | disclosed |
| US-5134137-A | CEPHALOSPORIN ANTIBIOTICS | THE UPJOHN COMPANY (US) | 1992-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200239460-A1 | TRPV1 ANTAGONISTS INCLUDING DIHYDROXY SUBSTITUENT AND USES THEREOF | TRPV1, TRPA1, TRPV3 | NR1I2 343/4885HTR2C 261/4885MAPT 3231/4885 |
| US-20170183337-A1 | TRPV1 ANTAGONISTS INCLUDING DIHYDROXY SUBSTITUENT AND USES THEREOF | TRPV1, TRPA1, TRPV3 | NR1I2 343/4885HTR2C 261/4885MAPT 3231/4885 |
| US-20150011529-A1 | AZETIDINE-SUBSTITUTED QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF | QDPR, P2RX5, P2RX1 | NR1I2 1812/4885HTR2C 164/4885MAPT 4629/4885 |
| US-20140045830-A1 | CYCLIC UREA- OR LACTAM-SUBSTITUTED QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF | QPCT, UBXN1, NQO2 | NR1I2 1121/4885HTR2C 2651/4885MAPT 3443/4885 |
| US-10918628-B2 | Treatment of synucleinopathies | SNCA, PARK7, GBA3 | NR1I2 3019/4885HTR2C 2043/4885MAPT 126/4885 |
| US-20190282552-A1 | Treatment of synucleinopathies | SNCA, PARK7, GBA3 | NR1I2 3019/4885HTR2C 2043/4885MAPT 126/4885 |
| US-20140329829-A1 | TRPV1 ANTAGONISTS INCLUDING DIHYDROXY SUBSTITUENT AND USES THEREOF | TRPV1, TRPA1, TRPV3 | NR1I2 343/4885HTR2C 261/4885MAPT 3231/4885 |
| US-20140350056-A1 | TRPV1 ANTAGONISTS INCLUDING DIHYDROXY SUBSTITUENT AND USES THEREOF | TRPV1, TRPV2, TRPA1 | NR1I2 171/4885HTR2C 78/4885MAPT 3212/4885 |
| US-10450308-B2 | TRPV1 antagonists including dihydroxy substituent and uses thereof | TRPV1, TRPA1, TRPV3 | NR1I2 343/4885HTR2C 261/4885MAPT 3231/4885 |
| US-20140128346-A1 | PHOSPHORUS-SUBSTITUTED QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF | P2RX4, P2RX1, P2RX5 | NR1I2 1628/4885HTR2C 1777/4885MAPT 4649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.